

# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/889,178	01/15/2002	Jean-Paul Briand	110072	8029	
7590 10/17/2005		EXAMINER			
Oliff & Berridge			AUDET, MAURY A		
PO Box 19928					
Alexandria, VA 22320			ART UNIT	PAPER NUMBER	
			1654	1654	

DATE MAILED: 10/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		09/889,178	BRIAND ET AL.				
		Examiner	Art Unit				
		Maury Audet	1654				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REF CHEVER IS LONGER, FROM THE MAILING Issions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communitor, period for reply is specified above, the maximum statutory perion to teeply within the set or extended period for reply will, by state eply received by the Office later than three months after the mand patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be ad will apply and will expire SIX (6) MONTHS froute, cause the application to become ABANDOI	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).				
Status							
<ul> <li>1) Responsive to communication(s) filed on 30 June 2005.</li> <li>2a) This action is FINAL. 2b) This action is non-final.</li> <li>3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.</li> </ul>							
Disposition of Claims							
5)⊠ 6)⊠ 7)□	Claim(s) 1-11,14,15 and 18 is/are pending in 4a) Of the above claim(s) is/are withd Claim(s) 8-11,14,15 and 18 is/are allowed. Claim(s) 1-7 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and	rawn from consideration.					
Application Papers							
9) The specification is objected to by the Examiner.  10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority (	under 35 U.S.C. § 119						
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
2) Notice 3) Infor	et(s) se of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/ or No(s)/Mail Date	<del></del>	ary (PTO-413)   Date.				

Art Unit: 1654

## **DETAILED ACTION**

An interview was held with Applicant on 09/30/2005, which resulted in the following amendments, to put the application in better condition for allowance: Claims 12-13, and 16-17 are cancelled without prejudice. Claims 14-15 have been rejoined. Claim 18 amended to now read: --A pharmaceutical composition comprising, as active ingredient, at least one pseudopeptide as claimed in claim 1, and a pharmaceutically acceptable excipient.-
It is requested that Applicant submit the above agreed upon amendments with the response to the present action.

However, an updated prior art search was conducted which revealed prior art teaching the invention (which was not found upon the initial prior art search or indicated in related PCT application's Search Report or Written Report by the European International Authority). Claims 1-11, 14-15, and 19 are pending and examined on the merits.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-7 rejected under 35 U.S.C. 102(a) as being anticipated by Limal et al. (Tetrahedron Letters 39 (1998) 4239-4242))("another", author Quesnel).

Limal et al. teach a pseudopeptide of at least 6 amino acids comprising at least one unit chosen from formula I or II (see page 4240 scheme 1, and page 4241 Fig. 1 and Table 2).

Art Unit: 1654

## Allowable Subject Matter

As to claims 7-11, 14-15, and 19, respectively, the reagent, kit, method, and composition comprising a pseudopeptide of at least 6 amino acids comprising at least one unit chosen from formula I or II is not reasonably taught or suggested by the prior art of record.

#### Conclusion

Claims 8-11, 14-15, and 18 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 571-272-0960. The examiner can normally be reached from 7:00 AM - 5:30 PM, off Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached at 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

MA 8/04/05

CHRISTOPHER R. TATE PRIMARY EXAMINER